Eris Lifesciences will acquire the remaining 30% stake in Swiss Parenterals for ₹423 crore via a preferential share allotment, making the subsidiary wholly owned. The transaction follows board approval on Monday.
Eris Lifesciences will acquire the remaining 30% stake in Swiss Parenterals for ₹423 crore via a preferential share allotment, making the subsidiary wholly owned. The transaction follows board approval on Monday.